Diagnosis of lung cancer in small biopsies and cytology

Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European respiratory society classification

William D. Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew G. Nicholson, Kim Geisinger, Yasushi Yatabe, Yuichi Ishikawa, Ignacio Wistuba, Douglas B. Flieder, Wilbur Franklin, Adi Gazdar, Philip S. Hasleton, Douglas W. Henderson, Keith M. Kerr, Iver Petersen, Victor Roggli, Erik Thunnissen, Ming Tsao

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

The new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification provides, for the first time, standardized terminology for lung cancer diagnosis in small biopsies and cytology; this was not primarily addressed by previous World Health Organization classifications. Until recently there have been no therapeutic implications to further classification of NSCLC, so little attention has been given to the distinction of adenocarcinoma and squamous cell carcinoma in small tissue samples. This situation has changed dramatically in recent years with the discovery of several therapeutic options that are available only to patients with adenocarcinoma or NSCLC, not otherwise specified, rather than squamous cell carcinoma. This includes recommendation for use of special stains as an aid to diagnosis, particularly in the setting of poorly differentiated tumors that do not show clear differentiation by routine light microscopy. A limited diagnostic workup is recommended to preserve as much tissue for molecular testing as possible. Most tumors can be classified using a single adenocarcinoma marker (eg, thyroid transcription factor 1 or mucin) and a single squamous marker (eg, p40 or p63). Carcinomas lacking clear differentiation by morphology and special stains are classified as NSCLC, not otherwise specified. Not otherwise specified carcinomas that stain with adenocarcinoma markers are classified as NSCLC, favor adenocarcinoma, and tumors that stain only with squamous markers are classified as NSCLC, favor squamous cell carcinoma. The need for every institution to develop a multidisciplinary tissue management strategy to obtain these small specimens and process them, not only for diagnosis but also for molecular testing and evaluation of markers of resistance to therapy, is emphasized.

Original languageEnglish (US)
Pages (from-to)668-684
Number of pages17
JournalArchives of Pathology and Laboratory Medicine
Volume137
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Cell Biology
Lung Neoplasms
Adenocarcinoma
Biopsy
Coloring Agents
Squamous Cell Carcinoma
Carcinoma
Neoplasms
Mucins
Terminology
Microscopy
Therapeutics
Light

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Diagnosis of lung cancer in small biopsies and cytology : Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European respiratory society classification. / Travis, William D.; Brambilla, Elisabeth; Noguchi, Masayuki; Nicholson, Andrew G.; Geisinger, Kim; Yatabe, Yasushi; Ishikawa, Yuichi; Wistuba, Ignacio; Flieder, Douglas B.; Franklin, Wilbur; Gazdar, Adi; Hasleton, Philip S.; Henderson, Douglas W.; Kerr, Keith M.; Petersen, Iver; Roggli, Victor; Thunnissen, Erik; Tsao, Ming.

In: Archives of Pathology and Laboratory Medicine, Vol. 137, No. 5, 05.2013, p. 668-684.

Research output: Contribution to journalArticle

Travis, WD, Brambilla, E, Noguchi, M, Nicholson, AG, Geisinger, K, Yatabe, Y, Ishikawa, Y, Wistuba, I, Flieder, DB, Franklin, W, Gazdar, A, Hasleton, PS, Henderson, DW, Kerr, KM, Petersen, I, Roggli, V, Thunnissen, E & Tsao, M 2013, 'Diagnosis of lung cancer in small biopsies and cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European respiratory society classification', Archives of Pathology and Laboratory Medicine, vol. 137, no. 5, pp. 668-684. https://doi.org/10.5858/arpa.2012-0263-RA
Travis, William D. ; Brambilla, Elisabeth ; Noguchi, Masayuki ; Nicholson, Andrew G. ; Geisinger, Kim ; Yatabe, Yasushi ; Ishikawa, Yuichi ; Wistuba, Ignacio ; Flieder, Douglas B. ; Franklin, Wilbur ; Gazdar, Adi ; Hasleton, Philip S. ; Henderson, Douglas W. ; Kerr, Keith M. ; Petersen, Iver ; Roggli, Victor ; Thunnissen, Erik ; Tsao, Ming. / Diagnosis of lung cancer in small biopsies and cytology : Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European respiratory society classification. In: Archives of Pathology and Laboratory Medicine. 2013 ; Vol. 137, No. 5. pp. 668-684.
@article{ffb838446c314b53be234086b22ce0fc,
title = "Diagnosis of lung cancer in small biopsies and cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European respiratory society classification",
abstract = "The new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification provides, for the first time, standardized terminology for lung cancer diagnosis in small biopsies and cytology; this was not primarily addressed by previous World Health Organization classifications. Until recently there have been no therapeutic implications to further classification of NSCLC, so little attention has been given to the distinction of adenocarcinoma and squamous cell carcinoma in small tissue samples. This situation has changed dramatically in recent years with the discovery of several therapeutic options that are available only to patients with adenocarcinoma or NSCLC, not otherwise specified, rather than squamous cell carcinoma. This includes recommendation for use of special stains as an aid to diagnosis, particularly in the setting of poorly differentiated tumors that do not show clear differentiation by routine light microscopy. A limited diagnostic workup is recommended to preserve as much tissue for molecular testing as possible. Most tumors can be classified using a single adenocarcinoma marker (eg, thyroid transcription factor 1 or mucin) and a single squamous marker (eg, p40 or p63). Carcinomas lacking clear differentiation by morphology and special stains are classified as NSCLC, not otherwise specified. Not otherwise specified carcinomas that stain with adenocarcinoma markers are classified as NSCLC, favor adenocarcinoma, and tumors that stain only with squamous markers are classified as NSCLC, favor squamous cell carcinoma. The need for every institution to develop a multidisciplinary tissue management strategy to obtain these small specimens and process them, not only for diagnosis but also for molecular testing and evaluation of markers of resistance to therapy, is emphasized.",
author = "Travis, {William D.} and Elisabeth Brambilla and Masayuki Noguchi and Nicholson, {Andrew G.} and Kim Geisinger and Yasushi Yatabe and Yuichi Ishikawa and Ignacio Wistuba and Flieder, {Douglas B.} and Wilbur Franklin and Adi Gazdar and Hasleton, {Philip S.} and Henderson, {Douglas W.} and Kerr, {Keith M.} and Iver Petersen and Victor Roggli and Erik Thunnissen and Ming Tsao",
year = "2013",
month = "5",
doi = "10.5858/arpa.2012-0263-RA",
language = "English (US)",
volume = "137",
pages = "668--684",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "5",

}

TY - JOUR

T1 - Diagnosis of lung cancer in small biopsies and cytology

T2 - Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European respiratory society classification

AU - Travis, William D.

AU - Brambilla, Elisabeth

AU - Noguchi, Masayuki

AU - Nicholson, Andrew G.

AU - Geisinger, Kim

AU - Yatabe, Yasushi

AU - Ishikawa, Yuichi

AU - Wistuba, Ignacio

AU - Flieder, Douglas B.

AU - Franklin, Wilbur

AU - Gazdar, Adi

AU - Hasleton, Philip S.

AU - Henderson, Douglas W.

AU - Kerr, Keith M.

AU - Petersen, Iver

AU - Roggli, Victor

AU - Thunnissen, Erik

AU - Tsao, Ming

PY - 2013/5

Y1 - 2013/5

N2 - The new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification provides, for the first time, standardized terminology for lung cancer diagnosis in small biopsies and cytology; this was not primarily addressed by previous World Health Organization classifications. Until recently there have been no therapeutic implications to further classification of NSCLC, so little attention has been given to the distinction of adenocarcinoma and squamous cell carcinoma in small tissue samples. This situation has changed dramatically in recent years with the discovery of several therapeutic options that are available only to patients with adenocarcinoma or NSCLC, not otherwise specified, rather than squamous cell carcinoma. This includes recommendation for use of special stains as an aid to diagnosis, particularly in the setting of poorly differentiated tumors that do not show clear differentiation by routine light microscopy. A limited diagnostic workup is recommended to preserve as much tissue for molecular testing as possible. Most tumors can be classified using a single adenocarcinoma marker (eg, thyroid transcription factor 1 or mucin) and a single squamous marker (eg, p40 or p63). Carcinomas lacking clear differentiation by morphology and special stains are classified as NSCLC, not otherwise specified. Not otherwise specified carcinomas that stain with adenocarcinoma markers are classified as NSCLC, favor adenocarcinoma, and tumors that stain only with squamous markers are classified as NSCLC, favor squamous cell carcinoma. The need for every institution to develop a multidisciplinary tissue management strategy to obtain these small specimens and process them, not only for diagnosis but also for molecular testing and evaluation of markers of resistance to therapy, is emphasized.

AB - The new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification provides, for the first time, standardized terminology for lung cancer diagnosis in small biopsies and cytology; this was not primarily addressed by previous World Health Organization classifications. Until recently there have been no therapeutic implications to further classification of NSCLC, so little attention has been given to the distinction of adenocarcinoma and squamous cell carcinoma in small tissue samples. This situation has changed dramatically in recent years with the discovery of several therapeutic options that are available only to patients with adenocarcinoma or NSCLC, not otherwise specified, rather than squamous cell carcinoma. This includes recommendation for use of special stains as an aid to diagnosis, particularly in the setting of poorly differentiated tumors that do not show clear differentiation by routine light microscopy. A limited diagnostic workup is recommended to preserve as much tissue for molecular testing as possible. Most tumors can be classified using a single adenocarcinoma marker (eg, thyroid transcription factor 1 or mucin) and a single squamous marker (eg, p40 or p63). Carcinomas lacking clear differentiation by morphology and special stains are classified as NSCLC, not otherwise specified. Not otherwise specified carcinomas that stain with adenocarcinoma markers are classified as NSCLC, favor adenocarcinoma, and tumors that stain only with squamous markers are classified as NSCLC, favor squamous cell carcinoma. The need for every institution to develop a multidisciplinary tissue management strategy to obtain these small specimens and process them, not only for diagnosis but also for molecular testing and evaluation of markers of resistance to therapy, is emphasized.

UR - http://www.scopus.com/inward/record.url?scp=84877938662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877938662&partnerID=8YFLogxK

U2 - 10.5858/arpa.2012-0263-RA

DO - 10.5858/arpa.2012-0263-RA

M3 - Article

VL - 137

SP - 668

EP - 684

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 5

ER -